Nadine Besson

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf et al. · Blood · 2011 · 461 citations

Life Sciences, Hematology, Oncology +9

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian et al. · Blood · 2012 · 318 citations · Full text

Medicine, Hematology, Oncology +6

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Hagop M. Kantarjian, Jörge E. Cortes, Dong‐Wook Kim et al. · Blood · 2013 · 150 citations · Full text

Medicine, Oncology, Pharmacology +16

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up

Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Dong‐Wook Kim et al. · American Journal of Hematology · 2014 · 117 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Peter C. Trask, David Cella, Nadine Besson et al. · Leukemia Research · 2011 · 54 citations

Medicine, Pharmacology, Pharmacotherapy +7